Clinical Trial Update: A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating a telomerase inhibitor to reverse trastuzumab resistance in HER2-positive breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Telomerase inhibitor (investigational)

Snippet

Sponsor: Indiana University | Conditions: Breast Neoplasms | Phase 1 | Status: COMPLETED